跳至主要内容
临床试验/NCT02153372
NCT02153372已完成1 期

Cell Based Therapy by Implanted Bone Marrow-derived Mononuclear Cells (BMC) for Bone Augmentation of Plate-stabilized Proximal Humeral Fractures

Goethe University2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2013年7月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10
试验地点
2
主要终点
safety

研究概览

简要总结

In the present phase-I clinical trial we investigate safety and feasibility of an augmentation with preoperatively isolated autologous BMC cells seeded onto ß-TCP in combination with an angle stable fixation (Philos plate®) for the therapy of proximal humeral fractures.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients aged between
  • years with proximal humerus fractures
  • indication for open reposition and internal stabilisation with a proximal fixed- angle plate for humerus (PHILOS, Synthes, Oberdorf, Swiss):
  • 2-, 3- or 4-fragment fracture according to NEer
  • dislocation of >10 mm between fragments and/or
  • angle of > 45° between fragments and/or
  • dislocation of tuberculum major > 5 mm
  • negative pregnancy test of premenopausal women
  • signed informed consent for surgery and participation in the clinical trial

排除标准

  • contraindications against administration of Investigational medicinal product (IMP) is pregnancy and nursing
  • dislocation fracture
  • known psychic disorder that leads to incompliance (e.g. dementia, schizophrenia, major depression)
  • pathologic fractures caused by other underlying diseases
  • fracture-induced nerve damage
  • tumor disease with recent adjuvant therapy or treatment during the last 3 months (e.g. chemotherapy, radiotherapy), untreated tumor diseases
  • known hypersensibility against components of the transplant
  • participation in a clinical trial during the last 3 months prior to this study

结局指标

主要结局

safety

时间窗: week 12 post surgery

Analysis of safety : morbidity of bone marrow punction local reaction (infection, delayed wound healing) systemic reaction (leucocytes, C-reactive protein, Interleukin-6, procalcitonin) fever (\> 38,5°C longer than 2 days)

次要结局

  • feasibility(week 12 post surgery)

研究者

发起方
Goethe University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ingo Marzi, MD Prof.

head physician

Goethe University

研究点 (2)

Loading locations...

相似试验

Cell Therapy by Bone Marrow-derived Mononuclear... | 临床试验